Journal
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Volume 132, Issue 2, Pages 228-236Publisher
OXFORD UNIV PRESS INC
DOI: 10.1309/AJCP4M2VUZCLDALN
Keywords
HER2; Breast carcinoma; Fluorescence in situ hybridization; FISH; Chromogenic in situ hybridization; CISH; American Society of Clinical Oncology/College of American Pathologists; ASCO/CAP; Chromosome 17 polysomy; Equivocal; Immunohistochemistry
Categories
Ask authors/readers for more resources
This study specifically addressed the performance of chromogenic in situ hybridization (CISH) on HER2 testing in 66 breast carcinomas with chromosome 17 polysomy and 49 carcinomas with an equivocal HercepTest (DakoCytomation, Carpinteria, CA) score by comparing CISH with corresponding FISH results at 2 test sites and evaluating intersite agreement of CISH results. For tumors with chromosome 17 polysomy, when using the manufacturers' criteria, the concordance values between CISH and FISH at site A, site B, and intersite CISH agreement were 95.8%, 95.5%, and 93.5%, respectively; when using the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria, the values were 100.0%, 100.0%, and 100.0%, respectively. For tumors with an equivocal HercepTest score, when using the manufacturers' criteria, the concordance values between the 2 methods at site A, site B, and intersite CISH agreement were 88.2%, 95.1%, and 91.1%, respectively; when using the ASCO/CAP criteria, the values were 96.7%, 97.3%, and 97.4%, respectively. These results indicate that CISH is reliable for testing these 2 types of tumors, especially when the ASCO/CAP criteria are used.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available